Home  »  Trending   »  Vertex Pharmaceuticals Incorporated (VRTX) Reveals...

Vertex Pharmaceuticals Incorporated (VRTX) Reveals an Earnings Mystery

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) went up by 0.63% from its latest closing price compared to the recent 1-year high of $305.95. The company’s stock price has collected 2.23% of gains in the last five trading sessions. Barron’s reported on 05/02/22 that Vertex Stock Falls as FDA Places Clinical Hold on Diabetes Treatment

Is It Worth Investing in Vertex Pharmaceuticals Incorporated (NASDAQ :VRTX) Right Now?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) scored a price-to-earnings ratio above its average ratio, recording 23.21 x from its present earnings ratio. Plus, the 36-month beta value for VRTX is at 0.45. Opinions of the stock are interesting as 15 analysts out of 28 who provided ratings for Vertex Pharmaceuticals Incorporated declared the stock was a “buy,” while 3 rated the stock as “overweight,” 10 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $310.71, which is $23.6 above the current price. VRTX currently public float of 255.88M and currently shorts hold a 1.11% ratio of that float. Today, the average trading volume of VRTX was 1.47M shares.

VRTX’s Market Performance

VRTX stocks went up by 2.23% for the week, with a monthly drop of -4.05% and a quarterly performance of 6.21%, while its annual performance rate touched 54.54%. The volatility ratio for the week stands at 2.35% while the volatility levels for the past 30 days are set at 2.78% for Vertex Pharmaceuticals Incorporated. The simple moving average for the period of the last 20 days is 0.22% for VRTX stocks with a simple moving average of 11.14% for the last 200 days.

Analysts’ Opinion of VRTX

Many brokerage firms have already submitted their reports for VRTX stocks, with Cantor Fitzgerald repeating the rating for VRTX by listing it as a “Overweight.” The predicted price for VRTX in the upcoming period, according to Cantor Fitzgerald is $365 based on the research report published on July 13th of the current year 2022.

Maxim Group, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $325. The rating they have provided for VRTX stocks is “Buy” according to the report published on June 01st, 2022.

SVB Leerink gave a rating of “Mkt Perform” to VRTX, setting the target price at $265 in the report published on May 23rd of the current year.

VRTX Trading at -0.26% from the 50-Day Moving Average

After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.21% of loss for the given period.

Volatility was left at 2.78%, however, over the last 30 days, the volatility rate increased by 2.35%, as shares sank -2.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.42% lower at present.

During the last 5 trading sessions, VRTX rose by +2.23%, which changed the moving average for the period of 200-days by +40.35% in comparison to the 20-day moving average, which settled at $285.97. In addition, Vertex Pharmaceuticals Incorporated saw 30.66% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at VRTX starting from Kewalramani Reshma, who sale 11,689 shares at the price of $305.06 back on Aug 15. After this action, Kewalramani Reshma now owns 99,598 shares of Vertex Pharmaceuticals Incorporated, valued at $3,565,846 using the latest closing price.

Arbuckle Stuart A, the EVP, COO of Vertex Pharmaceuticals Incorporated, sale 22,173 shares at $303.93 during a trade that took place back on Aug 15, which means that Arbuckle Stuart A is holding 45,278 shares at $6,738,991 based on the most recent closing price.

Stock Fundamentals for VRTX

Current profitability levels for the company are sitting at:

  • +36.94 for the present operating margin
  • +88.11 for the gross margin

The net margin for Vertex Pharmaceuticals Incorporated stands at +30.80. Equity return is now at value 30.10, with 22.90 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 4.46.

Is Cadence Bank (CADE) a Keeper?

Cadence Bank (NYSE:CADE) went down by -0.52% from its latest closing price compared to the recent 1-year high of $34.24. The company’s stock price has